Florida reaches $878 million opioid settlements with CVS, Teva, others
Reuters
Published Mar 30, 2022 08:39AM ET
Updated Mar 30, 2022 04:51PM ET
By Jonathan Stempel and Dietrich Knauth
(Reuters) - Florida has reached more than $878 million in settlements with CVS Health Corp (NYSE:CVS) and three drug companies to resolve claims and avert a trial next month over their roles in fueling an opioid epidemic in the third most populous U.S. state.
CVS will pay $484 million, Teva Pharmaceutical Industries (NYSE:TEVA) Ltd will pay $194.8 million, Abbvie Inc's Allergan (NYSE:AGN) unit will pay $134.2 million and Endo International (NASDAQ:ENDP) Plc will pay $65 million, Florida's attorney general Ashley Moody said in a statement on Wednesday.
Most of the money will be spent on opioid abatement. Teva will also provide $84 million of its generic Narcan nasal spray, which can temporarily reverse the effects of opioid overdoses.
The four companies denied wrongdoing in agreeing to settle. Endo's accord had been reached in January.
West Virginia reached a similar $26 million settlement with Endo on Wednesday, attorney general Patrick Morissey said in a press conference.
After the settlements, Florida and West Virginia will both begin pared-back opioid trials next week. West Virginia will proceed to trial on April 4 against Johnson & Johnson (NYSE:JNJ), Teva and Allergen. Florida will proceed to trial against pharmacy chain Walgreens, with jury selection scheduled to begin on April 5.
Walgreens said its 2012 opioid-related settlement with Florida covered the state's latest claims, and that it will defend against "unjustified attacks" on its pharmacists.
CVS and Teva said they would defend against other opioid lawsuits, and Teva said it is "actively" negotiating a national settlement of similar claims. Allergan said its settlement also covers claims for generic opioids it sold to Teva in 2016.
Endo did not immediately respond to requests for comment.
Florida announced the settlements nine days after Rhode Island reached similar accords with Teva and Allergan valued at $107 million.
More than 500,000 people have died from opioid overdoses in the past two decades nationally, including 75,673 in the year ending April 2021, according to the U.S. Centers for Disease Control and Prevention.
On Feb. 25, Johnson & Johnson and drug distributors AmerisourceBergen (NYSE:ABC) Corp, Cardinal Health Inc (NYSE:CAH) and McKesson Corp (NYSE:MCK) reached final settlements worth $26 billion over their roles in the nationwide epidemic.
Get The News You Want
State, local and Native American tribal governments in the United States have filed more than 3,300 lawsuits accusing drugmakers such as OxyContin maker Purdue Pharma of fueling opioid abuse, including by downplaying the risks of addiction.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.